These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 30095443)
1. Osteoblastic bone response mimicking bone progression during treatment with pembrolizumab in advanced cutaneous melanoma. Comito F; Ambrosini V; Sperandi F; Melotti B; Ardizzoni A Anticancer Drugs; 2018 Nov; 29(10):1026-1029. PubMed ID: 30095443 [TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
3. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases. Jespersen H; Bjursten S; Ny L; Levin M Lancet Oncol; 2018 Jun; 19(6):e327. PubMed ID: 29893264 [No Abstract] [Full Text] [Related]
4. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. Du Y; Cullum I; Illidge TM; Ell PJ J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153 [TBL] [Abstract][Full Text] [Related]
5. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma. Woodbeck R; Metelitsa AI; Naert KA Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748 [TBL] [Abstract][Full Text] [Related]
6. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma. Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271 [TBL] [Abstract][Full Text] [Related]
7. Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy. Krupitskaya Y; Eslamy HK; Nguyen DD; Kumar A; Wakelee HA J Thorac Oncol; 2009 Mar; 4(3):429-31. PubMed ID: 19247091 [TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab. Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A Clin Nucl Med; 2016 Feb; 41(2):156-8. PubMed ID: 26545022 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum. Salomon G; Maza A; Boulinguez S; Paul C; Lamant L; Tournier E; Mazereeuw-Hautier J; Meyer N Br J Dermatol; 2018 May; 178(5):1199-1203. PubMed ID: 29274233 [TBL] [Abstract][Full Text] [Related]
10. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. Robert C; Ribas A; Hamid O; Daud A; Wolchok JD; Joshua AM; Hwu WJ; Weber JS; Gangadhar TC; Joseph RW; Dronca R; Patnaik A; Zarour H; Kefford R; Hersey P; Zhang J; Anderson J; Diede SJ; Ebbinghaus S; Hodi FS J Clin Oncol; 2018 Jun; 36(17):1668-1674. PubMed ID: 29283791 [TBL] [Abstract][Full Text] [Related]
11. Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma. Boursi B; Werner TJ; Gholami S; Margalit O; Baruch E; Markel G; Eshet Y; Houshmand S; Shacham-Shmueli E; Mitchell TC; Mamtani R; Alavi A; Yang YX Melanoma Res; 2019 Jun; 29(3):318-321. PubMed ID: 30557217 [TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. Ivashko IN; Kolesar JM Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495 [TBL] [Abstract][Full Text] [Related]
13. [Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma]. Tietze JK; Heppt M; Angelova D; Ruzicka T; Berger F; Berking C Hautarzt; 2017 Aug; 68(8):632-638. PubMed ID: 28382381 [TBL] [Abstract][Full Text] [Related]
14. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT. Wachsmann JW; Ganti R; Peng F Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005 [TBL] [Abstract][Full Text] [Related]
15. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma. Roncati L Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Response of Unresectable Primary Cutaneous Melanoma to Immunotherapy Visualized With Reflectance Confocal Microscopy: A Report of 2 Cases. Navarrete-Dechent C; Cordova M; Postow MA; Pulitzer M; Lezcano C; Halpern AC; Rossi AM JAMA Dermatol; 2019 Mar; 155(3):347-352. PubMed ID: 30624578 [TBL] [Abstract][Full Text] [Related]
17. FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Israel O; Goldberg A; Nachtigal A; Militianu D; Bar-Shalom R; Keidar Z; Fogelman I Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1280-4. PubMed ID: 16791597 [TBL] [Abstract][Full Text] [Related]
18. Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET. Huyge V; Garcia C; Vanderstappen A; Alexiou J; Gil T; Flamen P Clin Nucl Med; 2009 Jul; 34(7):417-20. PubMed ID: 19542943 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. Longoria TC; Tewari KS Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741 [TBL] [Abstract][Full Text] [Related]
20. [Pembrolizumab for the treatment of melanoma: updates and perspectives.]. Chiarion Sileni V; Mandalà M; Queirolo P Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]